Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action

Aromatase inhibitors (AIs) reduce breast cancer recurrence and prolong survival, but up to 30% of patients exhibit recurrence. Using a genome-wide association study of patients entered on MA.27, a phase III randomized trial of anastrozole versus exemestane, we identified a single nucleotide polymorp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JCI Insight
Hauptverfasser: Cairns, Junmei, Ingle, James N., Dudenkov, Tanda M., Kalari, Krishna R., Carlson, Erin E., Na, Jie, Buzdar, Aman U., Robson, Mark E., Ellis, Matthew J., Goss, Paul E., Shepherd, Lois E., Goodnature, Barbara, Goetz, Matthew P., Weinshilboum, Richard M., Li, Hu, Bari, Mehrab Ghanat, Wang, Liewei
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Clinical Investigation 2020
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7455128/
https://ncbi.nlm.nih.gov/pubmed/32701512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.137571
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge